ConductScience.org, home

Comparison · NCT01083576-79cfa043

Paromomycin Alone Treatment vs WR 279,396: Number of Participants Who Obtained a Modified Final Clinical Cure of All Lesions

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Paromomycin Alone Treatment vs WR 279,396: Number of Participants Who Obtained a Modified Final Clinical Cure of All Lesions. Trial comparisons, record NCT01083576-79cfa043. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01083576-79cfa043

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5330.3010.752wilson
Risk in group 20.8670.6210.963wilson
Risk difference, group 1 minus group 2-0.333-0.585-0.00464newcombe hybrid score
Risk ratio, group 1 over group 20.6150.3681.03log
Odds ratio, group 1 over group 20.1760.0291.07log
Number needed to treat, for one fewer participant with the outcome on Paromomycin Alone Treatment than on WR 279,39631.71215from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Paromomycin Alone TreatmentParomomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days815OG000
Group 2WR 279,396WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days1315OG001

Outcome

Type
SECONDARY
Title
Number of Participants Who Obtained a Modified Final Clinical Cure of All Lesions
Description
Final cure as defined by the primary outcome measure AND and cure of all other lesions by Day 168. (100% re-epithelialization of all ulcerated lesions and resolution of all other type of lesions)
Time frame
168 days
Population
All randomized subjects were included in the mITT Analysis. All subjects met criteria for the evaluable subset.

Source ClinicalTrials.gov

Trial

Title
Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
NCT number
NCT01083576
Phases
PHASE2
Conditions
Leishmaniasis, Cutaneous
Interventions
WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream), Paromomycin Alone Cream (15% paromomycin topical cream)
Lead sponsor
U.S. Army Medical Research and Development Command
Results first posted
2014-05-15

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01083576-79cfa043